Department of Oral Pathology and Medicine, Okayama University, Japan.
Cancer Invest. 2010 Jun;28(5):495-500. doi: 10.3109/07357900903476778.
We analyzed mutation and expression status of human epidermal growth factor receptor 2 (Her2) in head and neck squamous cell carcinoma (HNSCC) using single strand conformation polymorphism (SSCP) mutation analysis and immunohistochemistry (IHC). Mutations were absent in all 85 cases. Out of 57 cases available for IHC, Her2 protein expression was negative (0) in 40 tumors (70%). Seventeen tumors (29.8%) expressed Her2, among these 13 tumors (22.8%) showed a weak (+1) expression and 4 (7%) showed a moderate expression (+2), none showed a strong (+3) expression. There was not a significant association between expression and any of the patients' clinical variables or prognosis. Our results suggest that Her2 may not be useful as a molecular target in HNSCC.
我们使用单链构象多态性（SSCP）突变分析和免疫组织化学（IHC）分析，对头颈部鳞状细胞癌（HNSCC）中人类表皮生长因子受体 2（Her2）的突变和表达状态进行了分析。在所有 85 例中均未发现突变。在 57 例可用于 IHC 的病例中，40 例肿瘤（70%）的 Her2 蛋白表达为阴性（0）。17 例肿瘤（29.8%）表达 Her2，其中 13 例（22.8%）表现为弱阳性（+1），4 例（7%）表现为中度表达（+2），无一例表现为强阳性（+3）。表达与任何患者的临床变量或预后均无显著相关性。我们的结果表明，Her2 可能不适用于 HNSCC 的分子靶向治疗。
